Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
monosialoganglioside
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Administration
- Intravenous
01
Overview
Monosialoganglioside (specifically GM1) is a glycosphingolipid biologic being investigated for its neuroprotective and neuroregenerative properties. In the context of a Phase 2 clinical trial led by Zhejiang Cancer Hospital (NCT03067753), it is being evaluated as a treatment for cerebral radiation necrosis, a serious complication following radiotherapy in patients with nasopharyngeal carcinoma. The drug is thought to function by limiting glutamate-mediated excitotoxicity and promoting nerve repair and regrowth. It is administered as an injection (100 mg/day) and compared against standard pulse steroid therapy (methylprednisolone/prednisolone).
- Brand names
- SygenCronassial
- Other names
- GM1 gangliosideGM-1 gangliosideGM 1 gangliosidemonosialoganglioside GM1GM1GM-1GM 1Monosialoganglioside Ganglioside
02
Targets
NTRK1 (Tropomyosin-related receptor kinase A)Neuronal cell membrane lipid domains
Beyond the preview
Go deeper on monosialoganglioside.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on monosialoganglioside.